Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03060486
Other study ID # endo1-2016
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 1, 2016
Est. completion date January 17, 2017

Study information

Verified date October 2018
Source Azienda Ospedaliero-Universitaria Careggi
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Blood contamination, such as apical microleakage, of root canal during preparation can be a major problem in endodontics. The purpose of this investigation was to evaluate the hemostatic properties of sulfonic/sulfuric acid solution used during root canal therapy in teeth with irreversible pulpitis.


Description:

A new device (HYBENX®) has been developed with the purpose of destroying dental biofilm. The material contains a concentrated aqueous mixture of hydroxybenzenesulfonic acid (37%) and hydroxymethoxybenzene acids (23%), sulfuric acid (28%), and water (12%).

The investigators planned a clinical and microbiological study using the decontaminant device in order to destroy the dental biofilm of root canals in cases of irreversible pulpitis. The ability of the decontaminant device to immediately stop bleeding during canal instrumentation was found out accidentally during the procedures of this still unpublished trial.

Due to this fact, the investigators were interested in evaluating the coagulation property of the material. Therefore, the aim of this prospective study is to describe a new approach to obtain hemostasis during root canal therapy using a sulfonic/sulfuric acid solution.

A total of 15 teeth with irreversible and acute pulpitis were included in the study. After manual and mechanical instrumentation of the root canal, a sterile paper point was introduced in the canal, and a first score was given based on the blood quantity.

The solution was used to irrigate the bleeding root canal; then a second sterile paper point was introduced, and the same score was assessed. The null hypothesis was that there is no difference in root canal bleeding before and after the use of the solution (⎧=0)


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date January 17, 2017
Est. primary completion date January 10, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 60 Years
Eligibility Inclusion Criteria:

- tooth affected by irreversible pulpitis, single-rooted teeth associated with healthy periodontium, physiologic sulcus depth (<3 mm), and absence of bleeding on probing of the involved teeth.

Exclusion Criteria:

- patients with systemic diseases using anticoagulants, antibiotics, or anti-inflammatory therapies in the last 30 days, patients with allergy to sulfur in any form, and pregnancy.

Study Design


Related Conditions & MeSH terms

  • Blood Contamination of Root Canal During Endodontic Therapy

Intervention

Device:
HYBENX®
The mixture was then introduced inside the root canal using the pre-dosed syringe for 20 seconds with a sterile paper point with and up and down movement. Finally, the canal was rinsed with sterile saline water using a syringe with a side-vented 30 G needle.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Dr Riccardo Pace

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline in Root Canal Bleeding Score After the root canal, shaping was performed, and a first sterile paper point was introduced in the root canal, up to the working length, to detect blood presence.
The root canal bleeding score (RCBS) was given as follows:
0: no blood detected
1: blood detected in the apical third of the root canal
2: blood detected both in the apical and the middle thirds of the root canal
3: blood detected in the whole root canal. After the use of the material a second sterile paper point was introduced in the root canal, up to the working length, to detect the presence of blood and an RCBS was assessed according the previous criteria
20 sec - before and after use
See also
  Status Clinical Trial Phase
Completed NCT03336853 - A New Approach for Controlling Hemostasis During Canal Treatment N/A